Table 4.

Diagnostic clinical and laboratory findings due to combined micro-macrothrombosis in aEA-VMTD and vEA-VMTD.

Combined Micro-Macrothrombosis due to aEA-VMTD (Gangrene Syndromes) (e.g., Sepsis)	Combined Micro-Macrothrombosis due to vEA-VMTD (Proximal/Central DVT) (e.g., Sepsis or after Vaccination)
Clinical features	Clinical features
Fever/fatigue/myalgia	Fever/fatigue/myalgia
TTP-like syndrome with thrombocytopenia and  MAHA	ITP-like syndrome (“Silent” ITP)
MODS (e.g., ARDS; encephalopathy)	MOIS (e.g., myocarditis; pericarditis)
Gangrene syndromes (e.g., SPG; limb gangrene)	VTE (e.g., VTE; CVST; PTE; SVT)
“Gangrene”	“Venous congestion syndrome”
Laboratory changes (demonstrated)	Laboratory changes (demonstrated or expected)
Endothelial (ULVWF path) markers	Endothelial (ULVWF path) markers
Consumptive thrombocytopenia	Consumptive thrombocytopenia
Overexpressed ULVWF/VWF antigen	Overexpressed ULVWF/VWF antigen
Increased FVIII activity	Increased FVIII activity
Increased thrombomodulin	Increased thrombomodulin
Endothelial epiphenomenon	Endothelial epiphenomenon
Positive ANA	Positive ANA
Positive anti-dsDNA	Positive anti-dsDNA
Positive anti-PL antibodies	Positive anti-PL antibodies
Positive PF4 antibodies	Positive PF4 antibodies
Tissue factor path markers	Tissue factor path markers
Positive D-dimer	Positive D-dimer
TF-bearing microvesicles in circulation	TF-bearing microvesicles in circulation (expected)

Abbreviation: ANA, antinuclear antibodies; CVST, cerebral venous sinus thrombosis; aEA-VMTD, arterial endotheliopathy-associated vascular micro-thrombotic disease; vEA-VMTD, venous EA-VMTD; MODS, multiorgan dysfunction syndrome; MOIS, multi-organ inflammatory syndrome; ITP, immune thrombocytopenic purpura; PF4, platelet factor 4; PL, phospholipids; PTE, pulmonary thromboembolism; SPG, symmetrical peripheral gangrene; SVT, splanchnic vein thrombosis; TTP, thrombotic thrombocytopenic purpura; VTE, venous thromboembolism.